Evaluation of Neuropsychiatric Function in Phenylketonuria: Psychometric Properties of the ADHD Rating Scale-IV and Adult ADHD Self-Report Scale Inattention Subscale in Phenylketonuria  by Wyrwich, Kathleen W. et al.
Avai lable onl ine at www.sc iencedirect .comV A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 4 0 4 – 4 1 21098-3015$36.00 – s
Published by Elsevie
http://dx.doi.org/10
E-mail: kathy.wy
* Address correspojournal homepage: www.elsevier .com/ locate / jva lEvaluation of Neuropsychiatric Function in Phenylketonuria:
Psychometric Properties of the ADHD Rating Scale-IV and Adult
ADHD Self-Report Scale Inattention Subscale in
Phenylketonuria
Kathleen W. Wyrwich, PhD1,*, Priscilla Auguste, MHS1, Ren Yu, MA1, Charlie Zhang, PhD2,
Benjamin Dewees, BS2, Barbara Winslow, PhD2, Shui Yu, PhD2, Markus Merilainen, MD2,
Suyash Prasad, MD2
1Evidera, Bethesda, MD, USA; 2BioMarin Pharmaceutical, Inc., Novato, CA, USAA B S T R A C TBackground: Previous qualitative research among adults and parents
of children with phenylketonuria (PKU) has identiﬁed inattention as an
important psychiatric aspect of this condition. The parent-reported
ADHD Rating Scale-IV (ADHD RS-IV) and the Adult ADHD Self-Report
Scale (ASRS) have been validated for measuring inattention symptoms
in persons with attention-deﬁcit/hyperactivity disorder (ADHD); how-
ever, their psychometric attributes for measuring PKU-related inatten-
tion have not been established. Objective: The primary objective of this
investigation was to demonstrate the reliability, validity, and respon-
siveness of the ADHD RS-IV and ASRS inattention symptoms subscales
in a randomized controlled trial of patients with PKU aged 8 years
or older. Methods: A post hoc analysis investigated the psychometric
properties (Rasch model ﬁt, reliability, construct validity, and respon-
siveness) of the ADHD RS-IV and ASRS inattention subscales using data
from a phase 3b, double-blind, placebo-controlled clinical trial in those
with PKU aged 8 years or older. Results: The Rasch results revealed
good model ﬁt, and reliability analyses revealed strong internal con-
sistency reliability (α Z 0.87) and reproducibility (intraclass correlation
coefﬁcient Z 0.87) for both measures. Both inattention measuresee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2015.01.008
rwich@evidera.com.
ndence to: Kathleen W. Wyrwich, Evidera, 7101 Wdemonstrated the ability to discriminate between known groups (P o
0.001) created by the Clinical Global Impression-Severity scale. Correla-
tions between the ADHD RS-IV and the ASRS with the Clinical Global
Impression-Severity scale and the age-appropriate Behavior Rating
Inventory of Executive Function Working Memory subscale were con-
sistently moderate to strong (r Z 0.56). Similarly, results of the change
score correlations were of moderate magnitude (r Z 0.43) for both
measures when compared with changes over time in Behavior Rating
Inventory of Executive Function Working Memory subscales. Conclu-
sions: These ﬁndings of reliability, validity, and responsiveness of both
the ADHD RS-IV and the ASRS inattention scales, in addition to content
validation results, support their use for the assessment of inattention
symptoms among persons with PKU aged 8 years or older in both
clinical and research settings.
Keywords: attention deﬁcit/hyperactivity disorder, inattention,
metabolic disorder, phenylketonuria, psychometrics.
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Phenylketonuria (PKU; OMIM 261600 and 261630) is the most
common inherited metabolic disorder [1], and is caused by a
functional deﬁcit in the phenylalanine hydroxylase enzyme,
which subsequently impairs the conversion of phenylalanine into
tyrosine [2]. If untreated, the accumulation of phenylalanine in the
serum and brain leads to severe intellectual disability, language
and social skill deﬁcits, seizures, and disruptive behavior [3,4].
With the onset of newborn screening in 1964, PKU is diagnosed at
birth in many countries and dietary intervention is immediately
initiated to prevent neurologically devastating complications.
Many individuals whose PKU is treated early avoid severe
complications and experience normal intellectual functioning [5].
Neurocognitive symptoms, however, are observed in some ofthese patients, even among those who adhere closely to dietary
treatment [6–8], and only modest elevations in phenylalanine
levels may impair high-level executive functioning [9–11]. Com-
mon neurocognitive symptoms include reduced attention
span/inattention symptoms [12–17] and hyperactivity/impulsiv-
ity [18–20].
A recent qualitative study documenting the physical, psycho-
logical, and cognitive symptom experiences of children and
adults with PKU found that inattention symptoms are often
reported by parents of children with PKU (Z8 years old) as well
as adults with PKU [17]. Moreover, the elicited inattention
symptoms were consistent with the inattention items of the
parent-reported ADHD Rating Scale-IV (ADHD RS-IV) and the
Adult ADHD Self-Reported Scale (ASRS), respectively. Most parent
and adult participants felt that these ADHD rating scales’ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 4 0 4 – 4 1 2 405inattention items were clear, comprehensive, and relevant for
assessing their children with PKU or self-ratings of their own
condition. Moreover, the ﬁndings of this content validity study
did not support the use of the ADHD RS-IV and the ASRS for the
measurement of hyperactivity symptoms in a PKU population.
Both the ADHD RS-IV [21] and the ASRS [22] are parent- and
self-reported instruments, respectively, developed to remain
aligned with the conceptualizations of attention-deﬁcit/hyper-
activity disorder (ADHD) symptoms presented in the Diagnostic
and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV)
[23]; both measures have shown evidence for strong reliability
and validity in ADHD populations [21,22] and have been used
widely in studies of children and adults with ADHD. Although
these measures have demonstrated the precision necessary to
achieve statistically signiﬁcant differences in PKU studies [24–26],
neither measure has been psychometrically validated for meas-
uring inattention symptoms in a PKU population. Having appro-
priately validated tools for measuring these important
neurocognitive symptoms would provide PKU clinical teams with
the needed tools to incorporate inattention symptoms screening
into routine clinical care. Therefore, the primary objective of this
investigation was to demonstrate the reliability, validity, and
responsiveness of the ADHD RS-IV and ASRS inattention symp-
toms subscales in a randomized controlled trial of patients with
PKU aged 8 years or older.Methods
Study Design and PKU Patient Populations
The PKU-016 study, also known as the PKU Assessment of Saprop-
terin Dihydrochloride Clinical Efﬁcacy in Neuropsychiatric Disor-
ders study, was a double-blinded, placebo-controlled, parallel-arm,
phase 3b randomized study in male and female participants aged 8
years or older with a conﬁrmed diagnosis of PKU (NCT01114737
[27]). The PKU-016 study included 206 participants from the United
States and Canada who were recruited across 36 clinical sites; full
inclusion and exclusion criteria are described elsewhere [27].
Participants were randomized 1:1 to receive sapropterin dihydro-
chloride or placebo and were treated for 13 weeks; subjects then
entered an open-label extension phase for a further 13 weeks.
Sapropterin dihydrochloride tablets (100 mg) were administered
orally, once daily, at a daily dose of 20 mg/kg after a meal at
approximately the same time each day over the course of the study.
The baseline, week 4, and week 13 visits from the randomized
treatment period were included in this post hoc investigation of the
psychometric properties of the ADHD RS-IV and the ASRS, as well
as other validated trial measures used to better understand the
measurement characteristics of these two instruments.
Measures
ADHD Rs-IV
The ADHD RS-IV assesses children’s ADHD symptoms and is
intended to be completed by a parent, guardian, or grandparent.
The full instrument is composed of two subscales (inattention
and hyperactive/impulsive symptoms), each with nine items that
assess the frequency of each of the ADHD symptoms and
behaviors in children and are rated using a four-point Likert-type
frequency scale (0 ¼ never or rarely, 1 ¼ sometimes, 2 ¼ often,
and 3 ¼ very often) with a recall period of “the past 1 month.”
Given the results of a recent content validity study of the ADHD
RS-IV in which only inattention symptoms were found to be
frequently reported by parents of children with PKU (Z8 years
old) [17], this analysis focused only on the summed nine-item
inattention subscale. In cases in which only one item score onthe ADHD RS-IV inattention subscale was missing, the item score
was imputed using the average of the eight nonmissing item
scores. The inattention subscale score ranges from 0 to 27, with
higher scores indicating greater inattention severity.
Adult ADHD Self-Report Scale
The full ASRS is a self-rated 18-item instrument developed to
assess the frequency of ADHD symptoms and behaviors in adults,
with ﬁve response options for items (0 ¼ never, 1¼ rarely, 2 ¼
sometimes, 3 ¼ often, and 4 ¼ very often) and a recall period of
the past 1 month. Similar to the ADHD RS-IV, the ASRS consists of
two parts. Part A measures inattention symptoms, and Part B
measures hyperactivity/impulsivity symptoms; this analysis
focused only on the nine-item summed scores from Part A. If a
response to a Part A item was missing, it was imputed by the
average of the nonmissing items in Part A; however, if response
to more than one of the items in Part A was missing, the ASRS
inattention score was set to missing. The ASRS inattention score
ranges from 0 to 36, with higher scores indicating greater
inattention severity.
Clinical Global Impressions-Improvement and Clinical Global
Impressions-Severity
The Clinical Global Impression-Improvement (CGI-I) scale is a
single clinician-reported item that assesses how much the
patient’s illness has improved or worsened relative to baseline
and is rated as 1 (very much improved), 2 (much improved), 3
(minimally improved), 4 (no change), 5 (minimally worse,) 6
(much worse), or 7 (very much worse). The CGI-I scale is widely
used and well validated, and is sensitive to changes in neuro-
psychiatric symptoms [28]. The Clinical Global Impression-
Severity (CGI-S) scale is another often-used single clinician-
reported item rating the severity of the patient’s illness at the
time of assessment relative to the clinician’s experience with
patients who have the same diagnosis (1 ¼ normal, not at all ill;
2 ¼ borderline ill; 3 ¼ mildly ill; 4 ¼ moderately ill; 5 ¼ markedly
ill; 6 ¼ severely ill; or 7 ¼ among the most extremely ill).
Behavior Rating Inventory of Executive Function Parent- and
Self-Report versions
The Behavior Rating Inventory of Executive Function (BRIEF) was
developed to systematically and quantitatively assess everyday
behavior by recording common descriptors of executive function-
related behaviors [29]. The BRIEF has been used previously in the
evaluation of neurocognitive function in children with PKU [30].
The BRIEF and the BRIEF-Adult Version (BRIEF-A) were adminis-
tered to assess changes in neurocognitive outcomes: parent
report for subjects younger than 18 years and self-report for
subjects 18 years or older, respectively. The Parent Form of the
BRIEF contains 86 items within eight clinical scales measuring
Behavioral Regulation (Inhibit, Shift, and Emotional Control) and
Metacognition (Initiate, Working Memory, Plan/Organize, Organ-
ization of Materials, and Monitor). Response options are based on
three-point Likert scale items that indicate the extent to which
the child’s behavior is “Never a problem” (1), “Sometimes a
problem” (2), or “Often a problem” (3). The recall period was 3
months. In these psychometric analyses, only the 10-item Work-
ing Memory subscale score from the BRIEF was used in the
psychometric analysis given its similarity to the concept of
inattention; summed subscale scores were normalized to t
scores, with a mean of 50 and an SD of 10, with higher subscale
scores indicating greater working memory problems. BRIEF
domain t scores are categorized as clinically signiﬁcant if 65 or
more [31]. The BRIEF-A used among adults contains 75 items
within nine clinical scales (Inhibit, Shift, Emotional Control, Self-
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and Organization of Materials), with the same three-point
response scale as the BRIEF [32]. The recall period for the BRIEF-
A was the past month. Only the normalized t scores from the
eight-item Working Memory subscale were incorporated into
these analyses, and t scores of 65 or more are considered
clinically signiﬁcant [32].Statistical Analysis
Analysis Population
The data in the psychometric analyses come from the intention-
to-treat population for Study PKU-016, deﬁned as all subjects
randomized to treatment. With the exception of the examination
of test-retest reliability, which was conducted in the stable placebo
group (deﬁned below in Reliability methods), all analyses were
conducted in the blinded data (pooled treatment and placebo
groups). Descriptive statistics were used to summarize the socio-
demographic and clinical data. Data were collected on character-
istics such as age, sex, ethnicity, and phenylalanine levels. Means,
SDs, medians, sample size, and percentages were reported.Item Response Distributions
To understand whether ﬂoor or ceiling effects exist for any ADHD
RS-IV and ASRS inattention symptom scale items, the number
and percentage of responders for each response option on each
item were calculated. Excessive use of a single response, deﬁned
as 50% or more of all respondents at the lowest or highest
response level, was used to identify any ﬂoor or ceiling effects.Rasch Item Analysis
Rasch analysis [33,34] was conducted to evaluate the spectrum of
inattention symptoms measured by the ADHD RS-IV and ASRS
inattention symptoms scale items using the children/parents and
adult data with no imputations at baseline. The Rasch analyses
allowed for the examination of each item’s psychometric proper-
ties in relation to the patient’s inattention symptoms level. It
assessed individual item ﬁt through a threshold map of response
option locations for each item, which aided in establishing and
understanding the monotonically increasing responses. Both
reliability indices and person separation were examined to
ascertain the consistency of the measures in the population(s)
(analogous to internal consistency and Cronbach α reliability) and
the sensitivity of the instruments to distinguish between high
and low respondents (person separation index). Generally, a
value of above 0.8 for both these indices indicates good perform-
ance of the instrument in relation to items and persons [35].
Individual item test-of-ﬁt was also examined, showing the chi-
square statistic for the ﬁt of the model to observed probabilities
for each item, where the value P o 0.05 was marked to indicate a
potentially misﬁtting item. Fit residuals report the size of misﬁt of
the person’s response to the response predicted by the model; in
general, ﬁt residuals above 3 (underﬁtting) or below 3 (over-
ﬁtting) are considered “high” and should cause model ﬁt to be
called into question for the item. Item maps were also created,
depicting the ﬁt of distribution of item thresholds to the distri-
bution of the patients’ estimated level of inattention symptoms.
Finally, differential item functioning (DIF) analyses were per-
formed for sex of the patient through an analysis of variance
(ANOVA) with sex (uniform DIF) and interaction of sex and
intercept (crossing DIF) on mean latent trait scores for each item.
The Rasch analyses were conducted using RUMM2030 software
[36] incorporating the polytomous Rasch model derived by
Andrich [33].Reliability
Test-Retest Reliability. Test-retest reliability of the ADHD RS-IV
and ASRS inattention subscales was assessed in the child and
adult data for subjects meeting the stable deﬁnition; stable
subjects were deﬁned as those in the placebo arm with no change
(score of 4 on the CGI-I scale) at week 4 (retest visit) [37].
Intraclass correlation coefﬁcients, which measure the repeatabil-
ity of measurements in a stable subsample, were used to assess
the reproducibility of the ADHD RS-IV and ASRS inattention
subscale scores at baseline and week 4, with intraclass correla-
tion coefﬁcients of more than 0.60 indicating substantial agree-
ment between test and retest scores [38].
Internal Consistency Reliability. Internal consistency reliability
was assessed in the items on the ADHD RS-IV and ASRS inattention
subscales to measure the extent to which the items on each
individual instrument were related to one another. To demonstrate
internal consistency reliability, the analysis was conducted in the
child and adult PKU populations using a Cronbach alpha (α) lower-
bound threshold of 0.70 to indicate that items in each of the
subscales were measuring the same construct [39].
Construct Validity
Known-groups Validity. Known-groups validity, the extent to
which scores from an instrument are different for groups of
participants who differ on a relevant clinical end point or other
indicator [40,41], was also assessed on the ADHD RS-IV and ASRS
inattention subscales using the CGI-S scale as a clinical measure
of the patient disease status at the baseline visit. Using the child
and adult data, separate known-groups analyses using ANOVA
were conducted comparing the ADHD RS-IV, ASRS, and pooled
ADHD RS inattention mean scale scores across categorizations of
the CGI-S scale, deﬁned as CGI-S scale scores of 1 to 2, CGI-S scale
scores of 3 to 5, and CGI-S scale scores of 6 to 7 [42].
Convergent Validity. Correlation coefﬁcients were assessed to
examine the convergent validity of the baseline ADHD RS-IV and
ASRS inattention subscale score with scores from the CGI-S scale
(Spearman correlation) and the BRIEF and BRIEF-A Working
Memory subscales (Pearson correlations). Thresholds for estab-
lishing convergent validity on the ADHD RS-IV and ASRS inat-
tention subscale score correlations with items or scales
measuring similar concepts were set at a magnitude of | r | Z
0.30, with moderate correlations deﬁned as 0.30 r | r |o 0.60 and
strong correlations deﬁned as | r | Z 0.60 [39].
Responsiveness. Responsiveness was assessed to determine the
extent to which the ADHD RS-IV and ASRS inattention subscale
scores detect change in participants known to have changed in
clinical status [41]. This ability to detect change was examined
using change scores calculated over the baseline to week 13 time
span. Spearman correlations between the ADHD RS-IV and ASRS
inattention subscale change scores and change scores for the
CGI-S scale, and Pearson correlations with the BRIEF and BRIEF-A
Working Memory subscales, were used. Similar to the convergent
validity analysis, thresholds for establishing responsiveness on
the ADHD RS-IV and ASRS inattention subscale score correlations
with items or scales measuring similar concepts were set at a
magnitude of | r | Z 0.30, with moderate correlations deﬁned as
0.30r | r |o 0.60 and strong correlations deﬁned as | r |Z 0.60 [39].
In addition, change in patient’s disease status was compared
between baseline and week 13 using the clinically signiﬁcant t
score level of 65 [31,32] through F test from ANOVA of ADHD
RS-IV and ASRS change scores of those patients who got worse
(Working Memory T score moved from o65 at baseline to Z65 at
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were Z65 or both were o65), or got better (moved from Z65 at
baseline to o65 at week 13). It was hypothesized that the F tests
would demonstrate differences between the mean inattention
scale change scores for these categories.Results
PKU Participant Population
Table 1 details the characteristics at baseline of the child and
adult subjects in this study. The mean age of the child and adult
populations was 12.9 and 30.3 years, respectively. The percentage
of females and males was the same or nearly the same for both
the child (50.0% males) and the adult (56.7% males) subgroups,
and a majority of the two subgroups were white (child: 97.7% and
adult: 95.0 %). Last, the children had lower average phenylalanine
levels than did adults (mean 570.5 and 1038.0, respectively),
although the participants’ PKU clinical severity spanned from
hyperphenylalaninemia through severe PKU [10] in each age
group, and some children’s phenylalanine levels were within
the normal range (o120 mmol/L) at baseline.Table 1 – Description of patient characteristics in
analysis of inattention symptoms in
phenylketonuria.
Participant
characteristic
Children*
(N ¼ 86)
Adults†
(N ¼ 120)
Age (y)
Mean  SD 12.9  2.8 30.3  9.8
Median (range) 12.9 (8.0–17.9) 28.2 (18.3–55.6)
Sex, n (%)
Male 43 (50.0) 68 (56.7)
Female 43 (50.0) 52 (43.3)
Ethnicity, n (%)
Hispanic or Latino 3 (3.5) 5 (4.2)
Not Hispanic or
Latino
83 (96.5) 115 (95.8)
Race, n (%)
American Indian
or Alaska Native
1 (0.8)
Asian 2 (2.3)
Black or African
America
2 (1.7)
White 84 (97.7) 114 (95.0)
Other 3 (2.5)
Phenylalanine level (μmol/L)
n 85 117
Mean  SD
Median (range)
570.5  350.4
507.0
(89.0– 1517)
1038.0  453.9
961.0
(208.0– 2185)
Baseline ADHD RS-IV, ASRS inattention‡
n 86 120
Mean  SD 11.7  7.3 13.5  5.2
Median (range) 10.0 (0.0–26.0) 13.1 (0.0–26.3)
ADHD RS-IV, ADHD Rating Scale-IV; ASRS, Adult ADHD Self-
Report Scale.
* Age o 18 y.
† Age Z 18 y.
‡ Note that the ADHD RS-IV score ranged from 0 to 27, and the
ASRS inattention score ranges from 0 to 36.Item Analysis
As presented in Table 2, no ADHD RS-IV and ASRS inattention
symptom subscale item exhibited ﬂoor or ceiling effects as
deﬁned by the lowest or highest response categories exceeding
the 50% threshold.
Rasch Item Analysis
Complete ADHD RS-IV baseline data from all 86 parents of
children were used when responses to the nine inattention
symptoms items were ﬁtted to the Rasch model. Alpha reliability
of 0.93 and person separation index of 0.91 indicated a reliable
instrument with very good ability to distinguish between patients
at different severity levels. Response categories of all items were
found to be ordered correctly, as indicated by the monotonically
increasing threshold parameters of all items (Fig. 1A), and all
item-ﬁt residuals were well within the range of a good model ﬁt
(between 3.0 and þ3.0) (Table 3). The P values of all model-ﬁt
chi-square were nonsigniﬁcant (P 4 0.05), also indicating good
model ﬁt (Table 3). Rasch model item map also showed that the
nine inattention items covered a wide range of severity of the
inattention symptoms and aligned well with the severity of the
sample (Fig. 2A). No DIF by sex was detected.
Similarly, ASRS data from all 120 adult patients at baseline
were used when responses to the nine inattention items were
ﬁtted to the Rasch model and response categories were ordered
correctly (monotonically increasing) for all items (Fig. 1B). Alpha
reliability and person separation index of 0.87 indicated an
instrument ﬁtting the modeled latent construct very well. All
item-ﬁt residuals for this measure were also within the range of a
good model ﬁt, and the P values of all model-ﬁt chi-square were
nonsigniﬁcant (P 4 0.05), also indicating good model ﬁt (Table 2).
The Rasch model item map showed that the nine inattention
symptoms items covered a wide range of severity of the symp-
toms and aligned well with the severity of the sample (Fig. 2B). At
the 5% level, only one ASRS item (“Trouble wrapping up”)
exhibited a mild amount of uniform DIF by sex (P ¼ 0.046).
Reliability
Results of test-retest reliability of the inattention symptoms
score of the ADHD RS-IV (intraclass correlation coefﬁcient ¼
0.87; n ¼ 25) and the ASRS (0.89; n ¼ 25) indicated outstanding
agreement [38] between the baseline and the week 4 retest visit in
the stable placebo-arm subsample. Internal consistency reliabil-
ity testing values for the two measures at baseline (ADHD RS-IV
and ASRS) were 0.93 and 0.87, respectively, demonstrating strong
internal consistency.
Construct Validity
Although no study subject had a baseline CGI-S scale score of 7
(among the most extremely ill subjects), the known-groups
validity of the inattention symptoms scores for the ADHD RS-IV
and the ASRS was demonstrated at baseline when groups were
constructed using CGI-S scale scores; statistically signiﬁcant (P o
0.05) overall and pairwise comparisons for the mean ADHD RS-IV
and ASRS inattention symptoms scores were observed (Table 4).
For convergent validity analysis, correlations with the CGI-S scale
were consistently moderate (r Z 0.56) in magnitude at baseline.
Correlations with the BRIEF Working Memory subscale were
strong in magnitude for both measures (r Z 0.76).
Responsiveness
The correlations between the ADHD RS-IV and the ASRS inatten-
tion symptoms change scores (baseline to week 13), and res-
pective change scores for the CGI-S scale (r Z 0.20), were small
Table 2 – Baseline item distribution for the ADHD RS-IV and ASRS inattention subscales.
Items Response options, n (%)
ASHD RS-IV (N ¼ 86) Never or rarely Sometimes Often Very often
Careless mistake 11 (12.8) 37 (43.0) 24 (27.9) 14 (16.3)
Difﬁculty sustaining attention 27 (31.4) 30 (34.9) 21 (24.4) 8 (9.3)
Not seem to listen 19 (22.1) 44 (51.2) 17 (19.8) 6 (7.0)
Not follow through 22 (25.6) 36 (41.9) 17 (19.8) 11 (12.8)
Difﬁculty organizing 26 (30.2) 23 (26.7) 19 (22.1) 18 (20.9)
Avoids tasks 19 (22.1) 33 (38.4) 15 (17.4) 19 (22.1)
Loses things 29 (33.7) 27 (31.4) 18 (20.9) 12 (14.0)
Easily distracted 17 (19.8) 23 (26.7) 24 (27.9) 22 (25.6)
Forgetful 20 (23.3) 33 (38.4) 18 (20.9) 15 (17.4)
Response options, n (%)
ASRS (N ¼ 120) Never Rarely Sometimes Often Very often
Careless mistakes 6 (5.0) 37 (30.8) 55 (45.8) 18 (15.0) 4 (3.3)
Difﬁculty keeping attention 4 (3.3) 22 (18.3) 54 (45.0) 24 (20.0) 16 (13.3)
Difﬁculty concentrating 14 (11.7) 30 (25.0) 42 (35.0) 24 (20.0) 10 (8.3)
Trouble wrapping up 20 (16.7) 42 (35.0) 30 (25.0) 21 (17.5) 7 (5.8)
Difﬁculty in order 11 (9.2) 33 (27.5) 39 (32.5) 25 (20.8) 12 (10.0)
Avoid or delay 9 (7.5) 18 (15.0) 27 (22.5) 45 (37.5) 21 (17.5)
Misplace things 7 (5.8) 27 (22.5) 33 (27.5) 32 (26.7) 21 (17.5)
Distracted 8 (6.7) 27 (22.5) 41 (34.2) 31 (25.8) 13 (10.8)
Problems remembering 19 (15.8) 39 (32.5) 35 (29.2) 16 (13.3) 11 (9.2)
ADHD RS-IV, ADHD Rating Scale-IV; ASRS, Adult ADHD Self-Report Scale.
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(r Z 0.43; P o 0.001) were moderate in magnitude and demon-
strated that these measures are sensitive enough to detect
change in other relevant measures. In addition, ANOVA of theFig. 1 – Inattention item thresASRS mean change scores demonstrated overall statistical sig-
niﬁcance (P ¼ 0.002; Table 5), with statistically signiﬁcant pair-
wise comparisons between the ASRS change scores of those
patients who got worse (mean ¼ 17.6) and of those whose scoreshold maps at baseline.
Table 3 – Inattention item-ﬁt statistics at baseline for the ADHD RS-IV and the ASRS.
Item Location SE Fit residual DF χ2 DF Probability
ASHD RS-IV (N ¼ 86)
Careless mistake 0.454 0.188 0.842 71.78 3.173 2 0.20
Difﬁculty sustaining attention 0.512 0.180 0.029 71.78 0.368 2 0.83
Not seem to listen 0.504 0.189 2.672 71.78 5.616 2 0.06
Not follow through 0.328 0.184 1.625 71.78 3.129 2 0.21
Difﬁculty organizing 0.125 0.167 0.018 71.78 3.647 2 0.16
Avoids tasks 0.309 0.171 0.102 71.78 0.242 2 0.89
Loses things 0.371 0.174 0.857 71.78 1.216 2 0.54
Easily distracted 0.696 0.170 0.049 71.78 1.394 2 0.50
Forgetful 0.131 0.173 1.211 71.78 1.320 2 0.52
ASRS (N ¼ 120)
Careless mistakes 0.287 0.135 0.004 101.89 0.508 2 0.78
Difﬁculty keeping attention 0.501 0.122 0.658 101.89 2.924 2 0.23
Difﬁculty concentrating 0.228 0.110 0.391 101.89 0.822 2 0.66
Trouble wrapping up 0.545 0.110 0.290 101.89 3.762 2 0.15
Difﬁculty in order 0.053 0.110 0.160 101.89 1.082 2 0.58
Avoid or delay 0.395 0.105 0.352 101.89 3.183 2 0.20
Misplace things 0.388 0.105 1.423 101.89 0.433 2 0.81
Distracted 0.153 0.112 0.060 101.89 1.246 2 0.54
Problems remembering 0.326 0.105 2.244 101.89 1.867 2 0.39
ADHD RS-IV, ADHD Rating Scale-IV; ASRS, Adult ADHD Self-Report Scale; DF, degrees of freedom; SE, standard error.
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both time points (mean ¼ 12.1; Po 0.001). The ADHD RS-IV mean
change scores were not signiﬁcantly different across the three
tested groups (P ¼ 0.149; Table 5).Discussion
The ADHD RS-IV [21] and the ASRS [22] measure parent- and
self-reported symptoms of ADHD, respectively, as delineated in
the DSM-IV [23] and all subsequent editions of the DSM (DSM-IV-
TR and DSM-V [43,44]), each with a nine-item inattention scale
and a nine-item hyperactive/impulsivity scale. There is strong
evidence of these instruments’ psychometric properties when
used in ADHD populations [21,22]. A recent qualitative inves-
tigation among parents of children with PKU and adults with
this condition suggested that the inattention symptoms meas-
ured in the ADHD RS-IV and the ASRS, respectively, are relevant
among persons with PKU (i.e., the questions reﬂected the
observations of parents of children with PKU and symptoms
reported by adults with PKU) [17]. This ﬁnding, however, did not
extend to the ADHD RS-IV and ASRS hyperactive/impulsive
scales. Using data from a recent clinical trial among children
and adults with PKU, this report detailed a quantitative exami-
nation of the measurement properties of these two measures of
inattention to further determine the usefulness of these instru-
ments in a population different from the condition that encour-
aged the original instruments’ development.
These results demonstrate that the nine-item ADHD RS-IV
and the ASRS scales are reliable, valid, responsive, and robust
measures of inattention among persons with PKU aged 8 years or
older. Rasch results demonstrated strong ADHD RS-IV and ASRS
inattention symptoms subscale performance, with the respec-
tive items working together as a single dimension and the item
difﬁculties adequately covering the clinical trial subjects’ range
of inattention. Moreover, there was no misordering of the
response options in the Rasch analyses of each measure, further
demonstrating that the items and responses were well under-
stood and used appropriately by the clinical trials’ adult subjectsand the parent responders. Similarly, high test-retest, person
separation, and Cronbach alpha reliability estimates demon-
strated the reproducibility and internal consistency of the scale
scores and items in each of the nine-item hyperactivity/impul-
sivity measures. Finally, criterion and construct validity tests, as
well as the ADHD RS-IV and ASRS’s ability to detect change over
time, reﬂected the previous content validity ﬁndings for persons
with PKU. The BRIEF and BRIEF-A Working Memory scales, both
known to measure executive function in children and adults
with ADHD [45,46], were strongly correlated with both ADHD RS-
IV and ASRS at baseline, and moderately correlated with change
in these two inattention symptoms measures. In addition,
longitudinal change scores on the BRIEF-A Working Memory
scales provided the opportunity to establish statistically signiﬁ-
cant ASRS change score comparisons.
Global items, such as the CGI-S scale, are questionable
measurement tools because speciﬁcs of “what is measured”
and “how the what is measured” that each clinician uses to
make the assessment are not clearly deﬁned and can result in
additional sources of measurement error [28]. In these analy-
ses, the CGI-S scale change scores did not provide a clear
criterion for understanding the ADHD RS-IV and ASRS change
over time between baseline and week 13, with weak correla-
tions that did not support the responsiveness of the inattention
scales.
The clinical trial data for this psychometric evaluation created
a valuable opportunity to test the ADHD RS-IV and ASRS meas-
urement characteristics by using the clinician-, parent-, and self-
reported measures that were incorporated into this phase 3b trial.
These validation results, however, are limited in several ways.
First, the results exclude inconclusive analyses comparing phe-
nylalanine levels collected during the trial and inattention sub-
scale scores. Previous research indicates that elevated levels of
phenylalanine may cause frontal system dysfunction and symp-
toms consistent with ADHD [47,48]. The speciﬁc mechanism
leading to the presence of these ADHD symptoms in persons
with PKU is currently unknown; however, it may be caused by
a direct toxic effect of phenylalanine levels. It has also been
suggested that reduced tyrosine levels in PKU may decrease
Fig. 2 – Inattention item map at baseline.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 4 0 4 – 4 1 2410dopamine and norepinephrine production in the central nerv-
ous system [24,25,49,50]. Results of this clinical trial popula-
tion showed a correlation between serum phenylalanine levels
and inattention scores in sapropterin responders and has been
discussed in the primary publication [27], but in the pooled
population of responders and nonresponders, this correlationwas weak. This may have been in part due to poor compliance
on the part of study subjects with a phenylalanine-restricted
diet.
The test-retest reliability results are limited in that few
placebo participants (n ¼ 25 in each age group) met the
deﬁnition of stable between baseline and week 4. In addition,
Table 4 – Known-groups validity: Inattention symptoms scores by CGI-S scale scores at baseline.
Scale CGI-S scale score at baseline, n, Mean  SD Overall F value
(P value)
Pairwise
comparisons*
Group 1 CGI-S
score 1–2
Group 2 CGI-S
score 3–5
Group 3 CGI-S
score 6
ADHD RS-IV 21, 5.8  4.5 58, 13.5  6.8 6, 16.8  8.2 13.11† A† B†
ASRS 20, 9.2  3.6 89, 14.1  5.0 10, 17.0  3.4 11.72† A† B†
ADHD RS-IV, ADHD Rating Scale; ASRS, Adult ADHD Self-Report Scale; CGI-S, Global Impression-Severity.
* Comparisons: A: Group 1 vs. Group 2; B: Group 1 vs. Group 3.
† P o 0.001.
Table 5 – Comparison of mean change scores of the ADHD RS-IV and ASRS inattention subscales across BRIEF
and BRIEF-A important change categories.
BRIEF (and BRIEF-A Working Memory change score groups)
n, Mean  SD
Overall F value
(P value)
Pairwise
comparison*
Instrument Group 1:
Got worse
Group 2:
Stayed the same
Group 3:
Improved
ADHD RS-IV 19, 13.8  5.2 53, 10.3  7.8 6, 9.5  2.4 1.95 (0.149) ANS
ASRS 11, 17.6  3.2 71, 12.1  4.9 1, 12.0 6.51 (0.002) A†
ADHD RS-IV, ADHD Rating Scale-IV; ASRS, Adult ADHD Self-Report Scale; BRIEF, Behavior Rating Inventory of Executive Function; BRIEF-A,
BRIEF-Adult version; NS, not signiﬁcant (P 4 0.05).
* Comparison: A: Group 1 vs. Group 2.
† P o 0.001.
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limited 1.0 to 1.0 theta range; therefore, there is less con-
ﬁdence in the precision outside of this range. In addition,
although the Rasch analysis found no misordering of the
response options, some thresholds (notably the response of
often for “Problems remembering” and “Difﬁculty keeping
attention” items and sometimes for the “Avoid or delay” of the
ASRS) were the most probable response for only a very narrow
range of the construct. The use of clinical trial data may also be
a limitation in the generalizability of these ﬁndings to the
routine care of persons with PKU, and future research should
conﬁrm the appropriateness in routine clinical care and a
better understanding of the neurobiology.Conclusions
Recently published management guidelines for the manage-
ment of PKU, and direction of future research into PKU,
emphasize the need to evaluate and manage such symptoms
of mental health and executive dysfunction in PKU [51,52].
This study’s ﬁndings on the robust measurement character-
istics for these two ADHD inattention symptoms measures in
a PKU population comprising both adults and children, in
concert with the previous qualitative support of their impor-
tance, establishes their appropriateness for measuring these
symptoms in persons with PKU. Accordingly, these ﬁndings
provide PKU clinical teams with validated tools to incorporate
inattention screening and ongoing assessment into routine
clinical care for persons with PKU aged 8 years or older.
Source of ﬁnancial support: BioMarin Pharmaceutical, Inc.,
supported this study.R E F E R E N C E S[1] Genetics Home Reference. Phenylketonuria. Available from: http://ghr.
nlm.nih.gov/condition/phenylketonuria. [Accessed November 19, 2013].
[2] Hoeks MP, den Heijer M, Janssen MC. Adult issues in phenylketonuria.
Neth J Med 2009;67:2–7.
[3] Fitzgerald B, Morgan J, Keene N, et al. An investigation into diet
treatment for adults with previously untreated phenylketonuria and
severe intellectual disability. J Intellect Disabil Res 2000;44:53–9.
[4] Yannicelli S, Ryan A. Improvements in behaviour and physical
manifestations in previously untreated adults with phenylketonuria
using a phenylalanine-restricted diet: a national survey. J Inherit Metab
Dis 1995;18:131–4.
[5] Bilder DA, Burton BK, Coon H, et al. Psychiatric symptoms in adults
with phenylketonuria. Mol Genet Metab 2013;108:155–60.
[6] Waisbren SE, Brown MJ, de Sonneville LM. et al. Review of
neuropsychological functioning in treated phenylketonuria: an
information processing approach. Acta Paediatr 1994;407:98–103.
[7] Brumm VL, Bilder D, Waisbren SE. Psychiatric symptoms and disorders
in phenylketonuria. Mol Genet Metab 2010;99(Suppl. 1):S59–63.
[8] Waisbren S, White DA. Screening for cognitive and social-emotional
problems in individuals with PKU: tools for use in the metabolic clinic.
Mol Genet Metab 2010;99(Suppl. 1):S96–9.
[9] Arnold GL, Kramer BM, Kirby RS, et al. Factors affecting cognitive,
motor, behavioral and executive functioning in children with
phenylketonuria. Acta Paediatr 1998;87:565–70.
[10] Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet
2010;376:1417–27.
[11] de Sonneville LM, Huijbregts SC, Licht R, et al. Pre-attentive processing
in children with early and continuously-treated PKU: effects of
concurrent Phe level and lifetime dietary control. J Inherit Metab Dis
2011;34:953–62.
[12] Realmuto GM, Garﬁnkel BD, Tuchman M, et al. Psychiatric diagnosis
and behavioral characteristics of phenylketonuric children. J Neurodev
Disord 1986;174:536–40.
[13] Brunner R, Berry H. Phenylketonuria and sustained attention: the
continuous performance test. J Clin Exp Neuropsychol 1987;9:68–70.
[14] Burgard P, Armbruster M, Schmidt E, et al. Psychopathology of patients
treated early for phenylketonuria: results of the German collaborative
study of phenylketonuria. Acta Paediatr 1994;407:108–10.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 4 0 4 – 4 1 2412[15] Weglage J, Pietsch M, Funders B, et al. Deﬁcits in selective and
sustained attention processes in early treated children with
phenylketonuria–result of impaired frontal lobe functions? Eur J
Paediatr 1996;155:200–4.
[16] Huijbregts SC, de Sonneville LM, Licht R, et al. Sustained attention and
inhibition of cognitive interference in treated phenylketonuria:
associations with concurrent and lifetime phenylalanine
concentrations. Neuropsychologia 2002;40:7–15.
[17] Mooney KH, Prasad S, Shaffer SK, et al. A formal approach to evaluating
the neuropsychiatric manifestations of PKU: assessing the content
validity of ADHD rating scales in phenylketonuria. Presented at: 63nd
Annual Meeting of the American Society of Human Genetics Boston,
MA, October 2013:22–6.
[18] Smith I, Beasley MG, Wolff OH, et al. Behavior disturbance in 8-year-old
children with early treated phenylketonuria: report from the MRC/
DHSS Phenylketonuria Register. J Pediatr 1988;112:403–8.
[19] Karimzadeh P, Tabarestani S. Promising medical treatment for
childhood psycho-cognitive problems. Neural Regen Res 2010;5:1663–7.
[20] Sadek AA, Emam AM, Alhaggagy MY. The impacts of phenylketonuria
(PKU) on children in Sohag University Hospital-Upper Egypt. J Am Sci
2012;8:1326–32.
[21] DuPaul GJ, Anastopoulos AD, Power TJ, et al. Parent ratings of attention
deﬁcit/hyperactivity disorder: factor structure, normative data, and
psychometric properties. J Psychopathol Behav Assess 1998;20:83–102.
[22] Adler LA, Spencer T, Faraone SV, et al. Validity of pilot Adult ADHD
Self- Report Scale (ASRS) to rate adult ADHD symptoms. Ann Clin
Psychiatry 2006;18:145–8.
[23] American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Health Disorders. (4th ed.). Washington, DC: American
Psychiatric Association, 1994.
[24] Antshel KM, Waisbren SE. Developmental timing of exposure to
elevated levels of phenylalanine is associated with ADHD symptom
expression. J Abnorm Child Psychol 2003;31:565–74.
[25] Antshel KM, Waisbren SE. Timing is everything: executive functions in
children exposed to elevated levels of phenylalanine. Neuropsychology
2003;17:458–68.
[26] Gassio R, Vilaseca MA, Lambruschini N, et al. Cognitive functions in
patients with phenylketonuria in long-term treatment with
tetrahydrobiopterin. Mol Genet Metab 2010;99(Suppl. 1):S75–8.
[27] Burton B, Grant M, Feigenbaum A, et al. A randomized, placebo-
controlled, double-blind study of sapropterin to treat ADHD symptoms
and executive function impairment in children and adults with
phenylketonuria [published online ahead of print November 26, 2014].
Mol Genet Metab. http://dx.doi.org/10.1016/j.ymgme.2014.11.011.
[28] Busner J, Targum SD, Miller DS. The Clinical Global Impressions scale:
errors in understanding and use. Compr Psychiatry 2009;50:257–62.
[29] Gioia GA, Kenworthy L, Isquith PK. Executive Function in the Real
World: BRIEF lessons from Mark Ylvisaker. J Head Trauma Rehabil
2010;25:433–9.
[30] Anderson VA, Anderson P, Northam E, et al. Relationships between
cognitive and behavioral measures of executive function in children
with brain disease. Child Neuropsychol 2002;8:231–40.
[31] Gioia GA, Isquith PK, Guy SC, et al. BRIEF: Behavior Rating Inventory of
Executive Function: Professional Manual. Lutz, FL: Psychological
Assessment Resources, Inc, 2000.
[32] Roth RM, Isquith PK, Gioia GA. BRIEF-A: Behavior Rating Inventory of
Executive Function - Adult Version. Lutz, FL: Psychological Assessment
Resources, 2005.[33] Andrich D. A rating formulation for ordered response categories.
Psychometrika 1978;43:561–73.
[34] Andrich D. An elaboration of Guttman scaling with Rasch models for
measurement. In: Brandon-Tuma N, ed. Sociological Methodology. San
Francisco: Jossey-Bass, 1985.
[35] Wright BD, Masters GN. Rating Scale Analysis. Chicago, IL: MESA Press,
1982.
[36] RUMM 2030. Rasch Unidimensional Measurement Models. Australia:
RUMM Laboratory Pty Ltd, 2010.
[37] Stenier DL, Norman GR. Health Measurement Scales: A Practical Guide
to Their Development and Use. (3rd ed.). Oxford: Oxford University
Press, 2002.
[38] Landis JR, Koch GG. The measurement of observer agreement for
categorical data. Biometrics 1977;33:159–74.
[39] Nunnally JC, Bernstein IH. Psychometric Theory. (3rd ed.). New York:
McGraw-Hill, 1994.
[40] Stewart AL, Hays RD, Ware JE. Methods of validating MOS health
measures. In: Stewart AL, Ware JE, eds. Measuring Functioning and
Well-being: The Medical Outcomes Study Approach. Durham, NC: Duke
University Press, 1992.
[41] Hays RD, Revicki DA. Reliability and validity, including responsiveness.
In: Fayers PM, Hays RD, eds. Assessing Quality of Life in Clinical Trials.
(2nd ed.) New York: Oxford University Press, 2005.
[42] Abetz L, Arbuckle R, Allen RP, et al. The reliability, validity and
responsiveness of the Restless Legs Syndrome Quality of Life
questionnaire (RLSQoL) in a trial population. Health Qual Life
Outcomes 2005;3:79.
[43] American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Health Disorders. 4th ed, text revision ed. Washington, DC:
American Psychiatric Association, 2000.
[44] American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Health Disorders. (5th ed.). Washington, DC: American
Psychiatric Association, 2014.
[45] Jarratt KP, Riccio CA, Siekierski BM. Assessment of attention deﬁcit
hyperactivity disorder (ADHD) using the BASC and BRIEF. Applied
Neuropsychol 2005;12:83–93.
[46] Adler LA, Dirks B, Deas P, et al. Self-reported quality of life in adults
with attention-deﬁcit/hyperactivity disorder and executive function
impairment treated with lisdexamfetamine dimesylate: a randomized,
double-blind, multicenter, placebo-controlled, parallel-group study.
BMC Psychiatry 2013;13:253.
[47] Diamond A, Ciaramitaro V, Donner E, et al. An animal model of early-
treated PKU. J Neurosci 1994;14:3072–82.
[48] Cho S, McDonald JD. Effect of maternal blood phenylalanine level on
mouse maternal phenylketonuria offspring. Mol Genet Metab
2001;74:420–5.
[49] Landvogt C, Mengel E, Bartenstein P, et al. Reduced cerebral ﬂuoro-L-
dopamine uptake in adult patients suffering from phenylketonuria.
J Cereb Blood Flow Metab 2008;28:824–31.
[50] Surtees R, Blau N. The neurochemistry of phenylketonuria. Eur J Pediatr
2000;159(Suppl. 2):S109–13.
[51] Cunningham A, Bausell H, Brown M, et al. Recommendations for the
use of sapropterin in phenylketonuria. Mol Genet Metab
2012;106:269–76.
[52] Camp KM, Parisi MA, Acosta PB, et al. Phenylketonuria Scientiﬁc
Review Conference: state of the science and future research needs. Mol
Genet Metab 2014;112:87–122.
